sacituzumab govitecan (Trodelvy) Report issue

Biologics mAb ADC Approved FDA Fast Track FDA Breakthrough Therapy FDA Accelerated Approval FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Payload: SN-38
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1530.8000 - $2002.3900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

immu-132 | sacituzumab govitecan

Organizations (34)

Research & Development (34)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Breast Neoplasms (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Hepatocellular (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 1/Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Drugs, Investigational (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Glioblastoma (Phase 2)

Liver Failure (Phase 1)

Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 1/Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 1/Phase 2)

Uterine Cervical Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 47
  • # of Trial Organizations: 34

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue